Agenus

Agenus company information, Employees & Contact Information

Explore related pages

Related company profiles:

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us at @agenus_bio. Our Community Guidelines are available at our website and at: https://agenusbio.com/community-guidelines/

Company Details

Employees
226
Founded
-
Address
3 Forbes Road, Lexington,massachusetts 02421,united States
Phone
(781)674-4400
Email
jo****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lexington, Massachusetts
Looking for a particular Agenus employee's phone or email?

Agenus Questions

News

Oklahoma City News - The Oklahoman - FinancialContent

Oklahoma City News - The Oklahoman FinancialContent

Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial - Oncodaily

Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial Oncodaily

Agenus Slashes Cash Burn by 50% While Advancing Promising Cancer Drug Program - Stock Titan

Agenus Slashes Cash Burn by 50% While Advancing Promising Cancer Drug Program Stock Titan

Harnessing the power of the immune system, Agenus Bio leads the charge in immuno-oncology - Manufacturing Today

Harnessing the power of the immune system, Agenus Bio leads the charge in immuno-oncology Manufacturing Today

Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus - Business Wire

Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus Business Wire

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs - FinancialContent

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs FinancialContent

Major Colorectal Cancer Trial Updates: Agenus to Present BATTMAN Phase 3 Study and BOT/BAL Data - Stock Titan

Major Colorectal Cancer Trial Updates: Agenus to Present BATTMAN Phase 3 Study and BOT/BAL Data Stock Titan

Agenus Reports Q1 2025 Financial Results and Key Business Updates - Stock Titan

Agenus Reports Q1 2025 Financial Results and Key Business Updates Stock Titan

Major Biotech Deal: Agenus Secures $141M from Zydus for Manufacturing Assets and Cancer Drug Rights - Stock Titan

Major Biotech Deal: Agenus Secures $141M from Zydus for Manufacturing Assets and Cancer Drug Rights Stock Titan

AI Breakthrough: Agenus and Noetik Join Forces to Revolutionize Cancer Patient Selection Using Virtual Cell Models - Stock Titan

AI Breakthrough: Agenus and Noetik Join Forces to Revolutionize Cancer Patient Selection Using Virtual Cell Models Stock Titan

Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 - Stock Titan

Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 Stock Titan

Top Agenus Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant